NT-proBNP and BNP as Biomarkers for Preeclampsia: A Systematic Review and Meta-Analysis. [PDF]
Suciu VE+9 more
europepmc +1 more source
Analytical Performance and Diagnostic Accuracy of Immunometric Assays for the Measurement of Plasma B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP [PDF]
Aldo Clerico+7 more
openalex +1 more source
Abstract Episodes of worsening heart failure (HF) are a major cause of unplanned hospitalizations. Their onset is usually preceded by an early increase in intracardiac pressures with subsequent worsening of symptoms due to congestion. Implantable devices allowing daily remote pulmonary artery pressure (PAP) monitoring are useful to identify early ...
Antoni Bayes‐Genis+13 more
wiley +1 more source
Predictive value of baseline serum sST2 and BNP levels for treatment efficacy in patients with heart failure. [PDF]
Zhang X, Zhang S.
europepmc +1 more source
Capability of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP as Indicators of Cardiac Structural Disease in Asymptomatic Patients with Systemic Arterial Hypertension [PDF]
Thomas Mueller+4 more
openalex +1 more source
Skeletal muscle and subcutaneous fat quantity as prognostic indicators in cardiac amyloidosis
Aims Disease‐related changes in body composition are associated with worse outcomes in chronic heart failure. In cardiac amyloidosis (CA), the prognostic value of direct body composition measures is understudied. Methods and results We identified 160 consecutive patients with CA (transthyretin [ATTR] or light chain [AL]) diagnosed between 2001 and 2021
Joshua Longinow+4 more
wiley +1 more source
Relationship of B‐type natriuretic peptide and anemia in patients with and without heart failure: A substudy from the Breathing Not Properly (BNP) Multinational Study [PDF]
Alan H.B. Wu+11 more
openalex +1 more source
The BNP Conundrum – Charecterisation of BNP Values for Cardiac and Non-Cardiac Causes
S. Bhattacharjee, A. Kumar
openaire +2 more sources
Myocardial ketone body oxidation contributes to empagliflozin‐induced improvements in cardiac contractility. Abstract Aims Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve cardiac performance and clinical outcomes in patients with heart failure, yet mechanisms underlying these beneficial effects remain incompletely understood.
Suzanne Nathalie Voorrips+11 more
wiley +1 more source